![intacept injection 25 mg intacept injection 25 mg](https://5.imimg.com/data5/OU/BW/LU/SELLER-78458833/intacept-25mg-injection-500x500.jpeg)
![intacept injection 25 mg intacept injection 25 mg](https://d3j7puhwqgd8ts.cloudfront.net/Pictures/1120xAny/1/1/5/6115_finalversion_ozempicsmccardpiupdate_894390.png)
In case of worsening of symptoms, patients were reverted to weekly regimen. They were then assessed at the end of 24 weeks for the achievement of “major improvement” and if achieved, were switched to once every 2 weeks dosages. The patients who failed to achieve “major improvement” at the end of 12 weeks were continued on weekly dose of prescribed biosimilar. , The primary endpoint was achievement of BASDAI 2 points) received same biosimilar every 2 weeks subsequently. Other parameters assessed at above-mentioned time points included ASAS-20 (Assessment of SpA International Society), ASAS-40, and ASAS-partial remission (ASAS-PR). ,, These were repeated at 12 weeks, 24 weeks, 52 weeks, and 104 weeks after starting the treatment with Etacept and at 12 weeks and 24 weeks after starting treatment with Intacept. Baseline assessment parameters included BASDAI, Bath Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Disease Activity Score (ASDAS), and NSAID consumption index. Patients with latent TB received rifampicin and isoniazid for 6 months, started simultaneously with anti-TNF therapy. In addition, hepatitis B surface antigen and anti-hepatitis C virus status were also obtained before starting anti-TNF therapy. Screening for latent tuberculosis (TB) included chest X-ray, interferon gamma release assay (“Quantiferon-TB-Gold“), and Mantoux test (1 TU). Women with pregnancy or who were breastfeeding were also excluded from the study. Patients with active tuberculosis, current or past history of hepatitis B, hepatitis C or human immunodeficiency virus, demyelinating disease, alcohol abuse, psychiatric illness, symptoms of severe and progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease, congestive heart failure, history of any form of cancer within the past 10 years, history of serious infection requiring hospitalization in the past 6 months, and history of any surgery in the past 12 weeks.Patients who did not complete at least 12 weeks of etanercept biosimilar therapy or.
![intacept injection 25 mg intacept injection 25 mg](https://5.imimg.com/data5/MQ/VQ/UC/SELLER-7169620/espogen-erythropoietin-injection-500x500-250x250.jpg)
#Intacept injection 25 mg trial#
Primary endpoint was BASDAI 4 Bath Ankylosing Spondylitis Disease Activity Index ) despite a 1-month trial of at least two NSAIDs (for axial symptoms only) with or without 3-month trial of DMARDs (for peripheral joint symptoms). For Etacept, week 52 and 104 data were also available. BASDAI, Bath Ankylosing Spondylitis Functional Index, and ASDAS and NSAID index were noted at baseline, 12, and 24 weeks. Patients achieving “major improvement” after 12 weeks (Ankylosing Spondylitis Disease Activity Score reduction by >2 points) received the dose every 2 weeks subsequently. Etanercept biosimilar (50 mg) was administered weekly for the first 12 weeks. Those with active disease (Bath Ankylosing Spondylitis Disease Activity Index >4), despite 1-month trial of two non-steroidal anti-inflammatory drugs (NSAIDs) (axial) and/or 3-month trial of disease modifying anti-rheumatic drugs (peripheral), received anti-TNF therapy. Methods: Clinical record of patients with axial and/or peripheral SpA (Assessment of SpA International Society criteria) registered during April 2013–September 2016 was retrieved. We present retrospective analysis of our experience with 2 etanercept biosimilars (Etacept and Intacept). It should be avoided by people who are allergic to latex, are pregnant or are planning to do so, have been in close proximity to a person with chicken pox.Background: Antitumor necrosis factor (TNF) drugs are highly efficacious in spondyloarthritis (SpA). It can also weaken the heart and lead to heart problems. It can also lead to nervous system problems such as sclerosis and seizures. The drug is especially dangerous for people with chickenpox. Patents with serious infections are advised to use it with caution and doctor's prescription. Some cases of cancers have also been reported in children. It can also aggravate or lead to serious conditions like fungal infections, sepsis, or tuberculosis. Some common side effects include pain, headache, itching, bruising, sore throat, redness, swelling and dizziness. Intacept 25Mg Injection is US FDA approved, but has some side effects as well. It is usually injected in the body and shows results in 2-10 weeks. Intacept 25Mg Injection blocks the TNF (tumor necrosis factor alpha) that causes inflammation.
![intacept injection 25 mg intacept injection 25 mg](https://5.imimg.com/data5/SELLER/Default/2021/5/IN/ZQ/IO/128495512/taxol-inject-250x250.jpg)
Intacept 25Mg Injection is a biological medicine which is used for treating inflammatory conditions such as rheumatoid arthritis, plaque psoriasis, ankylosing spondylitis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis.